This week in Drug Discovery (7-11 September 2026)
News round-up for 7-11 September 2026 by Megan Thomas, Content Team at DDW.
This week’s news roundup covers upcoming Drug Discovery Innovators & Investors (DDII) in-person events and forum updates, alongside the latest Phase II clinical data across coeliac disease, bronchiectasis and head and neck cancer.
The top stories:
Five reasons to attend Drug Discovery Innovators & Investors, London
The Drug Discovery Innovators & Investors (DDII) London, UK Conference brings together pharma and biotech companies, technology suppliers, academia, start-ups, spin-outs and investors for a focused day of discussion, collaboration and networking.
Drug Discovery Innovators & Investors Digital Forum offers certificate of attendance
Join us on 30 September for the Drug Discovery Innovators & Investors (DDII) Digital Forum, where experts from across the drug discovery ecosystem explore the technologies, strategies, therapies and investment trends shaping early-stage drug discovery.
Positive results for anti-IL-15 monoclonal antibody in coeliac disease
Teva Pharmaceutical has announced positive topline results from an ongoing Phase IIa study of TEV ‘408, an investigational anti-interleukin-15 monoclonal antibody, in adults with coeliac disease.
New Phase IIa data for RESP-X revealed at ERS Congress 2026
Infex Therapeutics has presented new data from its Phase IIa study of RESP-X (INFEX702), a first-in-class anti-virulence monoclonal antibody, in non-cystic fibrosis bronchiectasis (NCFB) patients colonised with Pseudomonas aeruginosa (Pa).
Phase II data show durable responses in head and neck cancer
QBiotics has announced positive results from its Phase II QB46C-H08 trial, with tigilanol tiglate achieving a 78% Objective Response Rate (ORR) in patients with head and neck solid malignancies who were refractory to standard of care.
